Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MorphoSys, a biotechnology company, and the University of Melbourne have announced that the US Patent & Trademark Office has confirmed that it will issue a US patent covering key uses of antibodies against GM-CSF.
Subscribe to our email newsletter
The patent stems from a provisional patent application filed in the US Patent & Trademark Office (USPTO) in 2000 by the University of Melbourne. In 2007, MorphoSys signed an agreement with the University of Melbourne, providing MorphoSys with an exclusive license to this patent family. The claims of the patent are directed to methods of ameliorating the effects of inflammation by administering to a patient an antibody directed against GM-CSF.
Human cytokine GM-CSF (Granulocyte macrophage-colony stimulating factor) is the target molecule of MorphoSys’s proprietary MOR103 antibody program for the treatment of rheumatoid arthritis (RA). MOR103 is said to be the first fully human antibody against GM-CSF in clinical trials. The drug could offer an innovative treatment option for RA based on a mechanism of action distinct from anti-TNF and other competing approaches, the company said.
Simon Moroney, CEO of MorphoSys, said: This new patent provides us with broad protection for our proprietary antibody program MOR103 in the US, which is by far the largest market for RA drugs. Our patent portfolio around this promising antibody-based program now extends beyond the specific MOR103 lead antibody, itself, and we anticipate that MOR103 will find application in other inflammatory disorders as well.